MAPPING THE CLINICAL COPD QUESTIONNAIRE ONTO EQ-5D VALUES

Published May 27, 2015
Rotterdam, The Netherlands – The Clinical COPD Questionnaire (CCQ) is a widely-used questionnaire to assess the effectiveness of chronic obstructive pulmonary disease (COPD) treatments. However, it is not a preference-based measure, and hence cannot be directly used to estimate the cost per quality adjusted life year (QALY) gained. Since many clinical trials include CCQ rather than preference-based measures, a successful mapping of the CCQ to the preference-based EuroQoL-5D (EQ-5D) would facilitate performing economic evaluations with COPD trial data. In a new study by the Institute for Medical Technology Assessment (iMTA) of Erasmus University, Rotterdam, a model was developed to predict EQ-5D values from CCQ data. The researchers obtained data from three trials including 5,751 observations with a broad range of COPD severity. Three approaches were used to estimate the statistical relationship between CCQ and EQ-5D in a development set: ordinary least squares, generalized linear models, and TOBIT regression. Performance was tested in the development data set and in external trial data sets. The best performing model was selected based on the mean absolute error and root mean square error of predicted versus observed values in both the development data set and external data sets. The researchers also developed models for different country-specific EQ-5D value sets. “The models predicted mean EQ-5D values that were similar to the observed mean values in the development set, but the EQ-5D values did significantly differ in external data sets. The mapping models underestimated the EQ-5D values for the mild health states, while they overestimated them in more severe health states. Therefore, the current model is only applicable in data sets that are similar to the development set. In general, mapping models should be used with caution.” said author Melinde Boland. The full study, “Mapping the Clinical Chronic Obstructive Pulmonary Disease Questionnaire onto Generic Preference-Based EQ-5D Values,” is published in Value in Health.

Related Stories

The Ozempic Paradox: How Spending Billions on Weight-Loss Drug Would Actually Reduce Overall Medicare Costs

Oct 14, 2025

Value in Health, the official journal of ISPOR—The Professional Society for Health Economics and Outcomes Research, announced today the publication of a landmark study by researchers at the University of Washington, Curta, Inc, and the University of North Carolina showing that broad Medicare coverage of semaglutide in diabetes, obesity, and liver disease could generate significant cost savings while delivering substantial health benefits to beneficiaries. The report, “Comprehensive Access to Semaglutide: Clinical and Economic Implications for Medicare,” was published in the October 2025 issue of Value in Health.

ISPOR Launches New Content on Whole Health

Sep 23, 2025

ISPOR announced that it has launched new website content on whole health, a topic of increasing importance as health systems across the globe grapple with providing the best possible healthcare to patients within constrained budgets.
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×